Business Wire

IL-ISACA

26.1.2021 17:18:12 CET | Business Wire | Press release

Share
ISACA Releases New Report on Privacy Trends, Obstacles and Predictions Ahead of Data Privacy Day

As Data Privacy Day approaches this week, ISACA has released a new survey report, Privacy in Practice 2021: Data Privacy Trends, Forecasts and Challenges , exploring past and future trends in privacy by design, privacy obstacles and privacy workforce.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210126005846/en/

Privacy by Design

Enterprises that report they always use privacy by design are more likely to be driven by a combination of compliance and ethics (62 percent vs. 52 percent total). They are also nearly two-and-a-half times more likely to be completely confident in their privacy team’s ability to ensure data privacy and achieve compliance with new privacy laws and regulations (24 percent vs. 10 percent total). However, there was not a meaningful difference in the number of privacy breaches they experienced in the last 12 months compared to all respondents. Approximately 10 percent of both groups reported breaches—a potentially underreported number.

Privacy Obstacles

Respondents identified other common privacy failures, including:

  • Lack of training or poor training (64 percent)
  • Failure to perform a risk analysis (53 percent)
  • Bad or nonexistent detection of personal information (50 percent)

Respondents cited privacy principles frameworks, experience-based credentials and privacy training as the most helpful methods in overcoming these obstacles.

Workforce Trends

Respondents indicated that they foresee an increased demand for technical privacy roles compared to legal/compliance roles (70 percent increase vs. 59 percent increase). However, technical privacy roles were more likely to be considered understaffed (46 percent vs. 33 percent).

Nevertheless, hiring managers have been filling these roles through training—47 percent noted they have been training non-privacy staff interested in moving into privacy roles. Ninety-two percent of respondents indicated that they have privacy staff who started their career in IT or security and moved into privacy and compliance.

“Organizations will continue needing a strong privacy workforce in the years ahead,” says Nader Qaimari, ISACA chief product officer. “As non-privacy professionals increasingly get opportunities to train for this career path and gain technical skills, it not only eases the privacy skills gap but enriches this workforce.”

The complimentary webinar, “Exploring Privacy Trends, Challenges & Predictions,” on 28 January 2021 at 12:00 PM EST / 5:00 PM (UTC) will explore the survey highlights. To learn more, visit www.isaca.org/education/online-events/lms_w012821 .

Access the Privacy in Practice 2021 survey report at www.isaca.org/privacy-in-practice-2021 . Learn more about ISACA’s privacy resources, including the Certified Data Privacy Solutions Engineer™ (CDPSE™) certification, at www.isaca.org/cdpse .

About ISACA

For more than 50 years, ISACA® (www.isaca.org ) has equipped individuals with knowledge, credentials, education and community to progress their careers and transform their organizations, and enables enterprises to train and build quality teams. ISACA leverages the expertise of more than 150,000 members who work in information security, governance, assurance, risk and privacy to drive innovation through technology. Its presence in 188 countries includes more than 220 chapters.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye